The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
By L. Emens, G. Middleton. Cancer immunology research, 2015
717 citations recorded by the source corpus.
Although cancer chemotherapy has historically been considered immune suppressive, it is now accepted that certain chemotherapies can augment tumor immunity. The recent success of immune checkpoint inhibitors has renewed interest in immunotherapies, and in combining them with chemotherapy to achieve additive or synergistic clinical activity. Two major ways that chemotherapy promotes tumor immunity are by inducing immunogenic cell death as part of its intended therapeutic effect and by disrupting strategies that tumors use to evade immune recognition. This second strategy, in particular, is dependent on the drug, its dose, and the schedule of chemotherapy administration in relation to antigen exposure or release. In this Cancer Immunology at the Crossroads article, we focus on cancer vaccines and immune checkpoint blockade as a forum for reviewing preclinical and clinical data demonstrating the interplay between immunotherapy and chemotherapy. Cancer Immunol Res; 3(5); 436–43. ©2015 AACR.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/e942c1ccaa6dfdb5c443ec74bddecbb02faf0ea2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Recent advances in therapeutic strategies for triple-negative breast cancer (2022, background): “For example, paclitaxel has pleiotropic immune-modulating effects because it helps mature dendritic cells shift the T-helper phenotype to promote the secretion of proinflammatory cytokines and enhance the activity of CD8+ T cells [129].”
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. (2017, background): “and also been recently shown in patients who had been previously treated with radiotherapy [31,32].”